{"schema_version":"secwatch.filing_event.v1","accession":"0001816590-26-000007","form_type":"8-K","ticker":"CMPS","cik":"0001816590","company_name":"COMPASS Pathways plc","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.282334+00:00","generated_at":"2026-05-16T02:30:23.530209+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Compass Pathways: Phase 3 COMP006 meets primary endpoint; COMP360 25mg shows -3.8 point MADRS reduction (p<0.001)","bullets":["COMP006: Two 25mg doses vs 1mg showed -3.8 point MADRS reduction (p<0.001) at Week 6, meeting primary endpoint.","39% of COMP006 25mg arm achieved clinically meaningful reduction (≥25% MADRS) at Week 6.","COMP005 single dose previously showed -3.6 point difference (p<0.001); durable effect through Week 26 after 1-2 doses.","Safety profile: TEAEs mostly mild/moderate, resolving within 24h; SAE suicidal ideation <1% across both trials.","Company requested FDA meeting to discuss rolling NDA submission for COMP360 in treatment-resistant depression."],"urls":{"canonical":"https://secwatch.observer/filing/0001816590-26-000007","json":"https://secwatch.observer/filing/0001816590-26-000007.json","markdown":"https://secwatch.observer/filing/0001816590-26-000007.md","text":"https://secwatch.observer/filing/0001816590-26-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/0001816590-26-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:30:23.530209+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}